Arrowhead Pharmaceuticals Inc. (ARWR)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arrowhead Pharmaceuticals Inc. chart...

About the Company

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

$567M

Total Revenue

377

Employees

$3B

Market Capitalization

-12.62

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ARWR News

Arrowhead Pharmaceuticals, Inc.

3mon ago, source: CNN

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms ...

ARWR Apr 2024 20.000 put

3d ago, source: Yahoo Finance

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the company's stock on March 6, 2024, according to a recent SEC filing. PASADENA, Calif., March 08, ...

Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value

12d ago, source:

Arrowhead Pharmaceuticals is estimated to be 26% overvalued based on current share price of US$34.08 The US$55.15 analyst ...

The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024

7d ago, source:

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After closing out 2023 with a 15.1% gain, the Russell 2000 ...

Arrowhead Pharmaceutical Gains Over Initiation Of Phase 1/2a Study Of ARO-DM1

10d ago, source:

Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) are climbing over 6 percent on Friday morning following the announcement of ...

Ionis stock jumps as MASH drug succeeds in mid-stage trial

on MSN ago, source:

Ionis Pharmaceuticals (NASDAQ:IONS) shares rose in early trading on Wednesday after the company reported positive results ...

Krystal Biotech confirms cancellation from Cowen conference due to CEO sickness

13d ago, source: Seeking Alpha on MSN

Krystal Biotech (NASDAQ:KRYS) earlier Tuesday canceled out of a presentation at a TD Cowen healthcare conference in Boston.

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

4d ago, source: Seeking Alpha

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation ...

Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

17h ago, source:

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Lipid-Nanoparticle Based Genomic Medicines ...

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

on MSN ago, source:

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT ...

Millet Flour Market to Reach US$ 7.8 Billion by 2034, Driven by Rising Demand for Gluten-Free Alternatives

1d ago, source: Future Market Insights

As per the latest analysis, the global millet flour market is expected to be valued at US$ 5.1 billion in 2024. It will likely exhibit steady growth, with millet flour sales growing at a CAGR of 5.3% ...

Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

7d ago, source: Finanznachrichten

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones. "2023 was a pivotal year ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...